Crysvita यूरोपीय संघ - आइसलैंडी - EMA (European Medicines Agency)

crysvita

kyowa kirin holdings b.v. - burosumab - hypophosphatemia, familial; hypophosphatemic rickets, x-linked dominant; osteomalacia - lyf til að meðhöndla beinsjúkdóma - crysvita is indicated for the treatment of x-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. crysvita is indicated for the treatment of fgf23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.

Saphnelo यूरोपीय संघ - आइसलैंडी - EMA (European Medicines Agency)

saphnelo

astrazeneca ab - anifrolumab - lupus erythematosus, systemic - Ónæmisbælandi lyf - saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (sle), despite standard therapy.

Enjaymo यूरोपीय संघ - आइसलैंडी - EMA (European Medicines Agency)

enjaymo

sanofi b.v. - sutimlimab - hemolysis; anemia, hemolytic, autoimmune - Ónæmisbælandi lyf - enjaymo is indicated for the treatment of haemolytic anaemia in adult patients with cold agglutinin disease (cad).

DUOKOPT (JOZ) Augndropar, lausn 20 mg/ml + 5 mg/ml आइसलैंड - आइसलैंडी - LYFJASTOFNUN (Icelandic Medicines Agency)

duokopt (joz) augndropar, lausn 20 mg/ml + 5 mg/ml

laboratoires thea s.a.s. - dorzolamidum hýdróklóríð; timololum maleat - augndropar, lausn - 20 mg/ml + 5 mg/ml

Fotil Forte Augndropar, lausn í stakskammtaíláti 5 mg + 40 mg/ml आइसलैंड - आइसलैंडी - LYFJASTOFNUN (Icelandic Medicines Agency)

fotil forte augndropar, lausn í stakskammtaíláti 5 mg + 40 mg/ml

santen oy* - pilocarpini chloridum nfn; timololum maleat - augndropar, lausn í stakskammtaíláti - 5 mg + 40 mg/ml